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Pediatric cardiac surgeryAbstract Postoperative chylothorax is a frequently encountered pathology occurring in up to 5%
of patients undergoing surgery for repair of congenital heart disease. Neck vein thrombosis can be
associated with chylothorax and may contribute to its severity and duration. Furthermore, neck
vessel thrombosis resulting in permanent vessel occlusion may hinder future management, diagnos-
tic studies and cardio-surgical interventions. In this report we are describing a neonate who devel-
oped chylothorax on the 7th post-operative day following open-heart surgery. The chylothorax was
linked to venous thrombosis in the cannulated right internal jugular vein with thrombus extending
to the right atrium. After using low dose tissue plasminogen activator (r-TPA) infusion, the thrombi
disappeared and the chylothorax resolved with no complications.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Case report
A newborn boy, weight 3 kg was diagnosed with transposition
of great arteries, intact ventricular septum, atrial septal defect
and patent ductus arteriosus. The patient was referred to us
from a primary care centre at the age of 9 days. On admission
the patient had umbilical venous catheter with prostaglandininfusion, the patient was suspected to be septic, and the
umbilical catheter was inserted immediately after birth, so
antibiotics started and UVC was replaced with a 4 French,
double lumen, right internal jugular (RIJ) central venous line
(CVL). Catheter insertion was done with ultrasound guidance
and was reported to be smooth and uneventful, and kept on
ﬁxed low dose heparin of 10 l/kg/h for line patency.
At 14 days of life, the patient underwent an arterial switch
operation and RIJ catheter was still in situ being used for the
infusion of the inotropic support and for invasive monitoring,
and a left atrial line inserted surgically to help monitoring
left atrial pressure. Shortly after surgery there was minimal
drainage from the single mediastinal tube. After the 5th post-
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Figure 2 Ultrasound picture showing short axis view for the
neck vessels resolution of the thrombosis of the right internal
jugular vein after r-TPA. RIJ: Right internal jugular, RIC: right
internal carotid.
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Figure 3 Trans-thoracic ECHO picture, subcostal Biatrial view
showing two thrombi, one in the Right Atrium (RA) measuring
(0.6 · 1 cm) and the other in the Left atrium (LA) (0.5 · 0.7 cm).
RA: right atrium, LA: left atrium.
172 S.R Ismail et al.operative day, the patient developed thrombocytopenia that
was managed with antibiotics presuming septic related causes.
Blood cultures remained negative. Echocardiography (ECHO)
at that time showed, no residual defects, and no thrombi or
vegetations in the heart or major veins. On the 7th post-op-
erative day signiﬁcant right-sided pleural effusion developed
which required chest tube insertion and drainage of a sig-
niﬁcant amount of milky ﬂuid that was conﬁrmed by laborato-
ry analysis to be chyle. The patient was kept nil per mouth
(NPO) along with total parenteral nutrition administration.
Doppler ultrasound of neck vessel showed thrombosis of right
internal jugular vein with thrombus extending to right atrium
(Figs. 1 and 2). Additionally ECHO at that time showed two
thrombi, one in the Right Atrium (RA) measuring (0.6 · 1 cm)
and the other in the Left atrium (LA) (0.5 · 0.7 cm) (Fig. 3).
We investigated the patient for possibility of hyper-coagulable
disease, but all investigations were negative. The patient was
managed conservatively with anti-coagulation in form of frac-
tionated heparin infusion with no evidence of clinical improve-
ment in venous obstruction despite satisfactory anticoagulation
(PTT: double the control value). Furthermore, the chyle drai-
nage remained signiﬁcant averaging 64 ml/kg/day and total of
1.5 l in 8 days. The risk/beneﬁt ratio of using (r-TPA) infusion
in recently operated neonate was discussed and judged to be in
favor of beneﬁts to start low dose (r-TPA) (0.05 mg/kg/h) for
6 h followed by heparin infusion.We repeated ECHO 24 h after
the ﬁrst dose of (r-TPA) infusion and the RA thrombus was
noted to be smaller in size, while the LA thrombus completely
disappeared (Fig. 4), so a second low dose (r-TPA) over 6 h was
also ensued. ECHO and ultrasonography imaging after the
second (r-TPA) dose showed complete resolution of the throm-
bi in the RIJ vein (Fig. 6), and in both atria, with simultaneous
dramatic decrease in the chylothorax drainage followed by
complete recovery and there were no complications (Fig. 5),
Head ultrasound was done before and after (r-TPA) and ruled
out any cerebral hemorrhage.
2. Discussion
Venous thromboembolic disease (VTE) is an increasingly rec-
ognized clinical entity in children who are surviving seriousvein  RIJ
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Figure 1 Ultrasound picture showing short axis view for the
neck vessels with partial thrombosis of the right internal jugular
vein. RIJ: Right internal jugular, RIC: right internal carotid.underlying disorders such as congenital heart disease (CHD).
Children with CHD are the largest identiﬁable group account-
ing for 1/3 of children with venous thrombosis.1 In the general
pediatric patient’s population, the most important risk factor
for VTE is the use of Central venous lines (CVL), which are
present in 30–70% of children with VTE.2,3 Central venous
lines appear to be major risk factors for VTE, based on the
close anatomical relationship found between catheters position
and thrombi location.4 Pathogenic mechanisms of CVL related
VTE include vessel wall trauma at insertion site, obstruction of
venous ﬂow, endothelial damage by CVL adhering to the
venous wall, and the intravascular presence of a foreign sur-
face.5,6 About two thirds of VTE in children occur in the upper
venous system reﬂecting the most common location of CVL
placement.3 There is major variability in the reported preva-
lence of VTE in pediatric population. Petaja et al. described
a prevalence of VTE after pediatric surgery, which was higher
in neonates 5.8% compared to non-neonates 1.1%. Mortality
was (40%) in children with VTE compared to non-VTE
(8.3%) (P< 0.001).21 In another prospective randomized
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Figure 4 Trans-thoracic ECHO picture, subcostal Biatrial view
showing resolution of the left atrial thrombus and a small residual
part of the right atrial thrombus after the ﬁrst r-TPA dose. RA:
right atrium, LA: left atrium.
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Figure 5 Rate of chylothorax drainage over 25 days (ml/day).
This ﬁgure is showing the trend of the chylothorax drainage and
the dramatic decrease in the rate of drainage after the second dose
of TPA (day 10). Ml: milliliter. TPA: Tissue plasminogen activator.
Successful use of r-TPA for management of chylothorax 173controlled study the authors reported VTE rate much higher
with a prevalence of 42.5% in infants under 1 year of age, an
age group that likely had an increased prevalence of VTE when
compared to older children. However, these data indicate a
highly signiﬁcant prevalence of VTE in infants and neonates.22
Manlhiot noted an 11% incidence of arterial or venous vessel
thrombosis in pediatric cardiac surgery patients. Sixteen per-
cent of these intravascular thromboses were associated with
CVL.23 Cardiopulmonary bypass presents a hemostatic chal-
lenge associated with an abundance of prothrombotic risk fac-
tors.24 Exposure of blood components to a large synthetic
surface causes disturbances in platelet function, coagulation
factors, ﬁbrinolytic system, and physiological inhibitors of
coagulation.25 This ultimately leads to platelet activation,
which is also exaggerated by the use of deep hypothermic cir-
culatory arrest.26 Activated platelets provide important proco-
agulant activity by expressing binding sites for speciﬁc
coagulation proteins. The activation period tends to be longerand its intensity more pronounced in children with cyanotic
congenital heart disease than in healthy infants.27 Along with
direct activation of the coagulation cascade, cardiopulmonary
bypass triggers a global inﬂammatory response in a positive
feedback mechanism, leading to further activation of the
coagulation system and other systemic manifestations.24 Neo-
nates already have low levels of antithrombin, protein S and
protein C activity (typically between 20% and 60% of adult
levels), contact factors (XI, XII, PK, HMWK), and vitamin
K-dependent factors (II, VII, IX, X) (all_70% of adult val-
ues).28 Many of these differences are associated with lower
capacity to inhibit thrombin generation, increased heparin
clearance, and decreased sensitivity to anticoagulants, par-
ticularly to standard heparin, the most commonly used agent
during and after surgery.29 The initiation of cardiopulmonary
bypass can result in a further 50% decrease in circulating
coagulation factors and antithrombin levels, in addition to a
70% drop in platelet counts.30 In addition to the newly
acquired hypercoagulable state and functional resistance to
anticoagulation, physical factors increase the risk of thrombo-
sis in this population. The presence of an indwelling access line
is generally considered one of the most important risk factors
for thrombosis in pediatric patients, and _20% of patients with
an indwelling access line will develop a related thrombus.31,32
In general we use in our practice low dose heparin infusion
10 IU/kg/hr. in infants and neonates to minimize the risk of
CVL thrombosis as supported by some evidence,7 but throm-
bosis developed in our patient in spite of that. The beneﬁts of
heparin prophylaxis for VTE prevention in children with CVL
are unproven. In a recently published evidence-based, clinical
practice guideline by Monagle et al.23 they recommended
against routine thrombolysis.
Chylothorax is a potentially life-threatening disorder that
can lead to serious metabolic, immunologic and nutritional
complications. Initial management is the same regardless of
the cause of chylothorax. Low fat diet, total parenteral nutri-
tion (TPN), Octeriotide, and in some cases treatment of the
cause is essential for the resolution of chyle drainage.8 Chy-
lothorax occurs postoperatively in up to 4% of all pediatric
patients undergoing surgery for congenital heart disease.8 Ear-
ly post-operative chylothorax is usually seen as result of intra-
operative thoracic duct injury. However, late presenting chy-
lothorax may have other possible causes that have been
described such as venous thrombosis, and high venous pres-
sure.14 Irrespective of its causes chylothorax has major impact
on after cardiac surgery outcome. It has been associated with
prolonged ventilator dependence, increased length of hospital
stay, malnutrition, nosocomial infection, and death.8 Though
multiple case series and case reports.9–12 have suggested an
association between central venous thrombosis (CVT) and
chylothorax development, no large, controlled studies have
veriﬁed this association. The connection between chylothorax
and central venous thrombosis is suggested to be a causative
relation supported by several case reports and series.13,10–12
Le Coultre et al. described seven out of twenty-four (29%)
pediatric patients with postoperative chylothorax that was
associated with superior vena cava (SVC) obstruction; ﬁve of
them had bilateral chylothorax. Chylothoraces secondary to
venous hypertension and thrombosis have a longer interval
between operation and diagnosis compared with direct trauma
as well as a longer duration and larger volume of chylous
drainage.14 The mechanism for the development of chylotho-
174 S.R Ismail et al.rax following major neck vein obstruction is poorly under-
stood. Increased venous pressure or obstruction of lymphatic
ﬂow at the junction of the thoracic duct and the venous system
is thought to cause a secondary increase in lymphatic back-
pressure within the thoracic duct. Subsequent distention and
insufﬁciency of intrathoracic lymphatics may result in leakage
of lymph into the pleural or pericardial space or both.15–17
Central venous thrombosis is commonly treated with systemic
anticoagulation, catheter removal, Catheter directed throm-
bolytic therapy or systemic thrombolytic therapy. Manlhiot
et al. reported Thrombosis in the population of pediatric after
open heart surgery, 87% of patients needed treatment, with
108 patients (63%) treated with low-molecular-weight heparin,
76 (44%) treated with unfractionated heparin, and 12 (7.0%)
treated with warfarin. Thrombolytic therapy was used for 9
patients (5.3%) with 19 obstructed vessels, and mechanical
thrombus catheter removal was performed in 25 patients
(15%) with 28 obstructed vessels/intracardiac thrombi.31
Thrombolytic agents are occasionally indicated in patients
with symptomatic thrombi. Manghat et al. published a case
report of Down syndrome with chylothorax that was success-
fully managed by catheter-directed thrombolysis and angio-
plasty of the venous occlusions.18 The dose of r-TPA is still
a subject of debate; it was addressed in many studies with dif-
ferent regimens. High doses of rTPA can increase rates of seri-
ous bleeding complications in children,33 but this risk should
decrease with lower rTPA doses.20 Weiner et al.19 used an ini-
tial dose of 0.1 mg/kg/h of r-TPA for 6 h that was increased by
0.1 mg/kg/h at 6-h intervals to a maximum of 0.5 mg/kg/h.
Two out of seven patients (1 term and 1 small preterm neo-
nate) died at the highest infusion rate of 0.5 mg/kg/h due to
severe bleeding complications. Wang et al.20 reported throm-
bolysis with a low-dose regimen (0.01–0.06 mg/kg/h). Eight
patients in this study were neonates at day 1–2 weeks of age
with complete lysis of the thrombus and no bleeding complica-
tions. In the present case there was a high risk of bleeding that
can be detrimental, so we elected to use low dose regimen of
infusion 0.05 mg/kg/h for 6 h. 24 h later and after careful
assessment we judged that another dose could be beneﬁcial,
which did achieve successful results as the venous and atrial
thrombi resolved completely, and the chylothorax also
resolved without any bleeding complications.
In conclusion chylothorax associated with venous thrombo-
sis can occur particularly in neonates having CVL. Central
venous catheter is known risk for thrombosis and it should
be removed as soon as not needed. Low dose r-TPA can be
used effectively with satisfactory results in cases of symptomat-
ic thrombosis leading to complications. The beneﬁts of r-TPA
should be measured against its risk.Conﬂict of Interest
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for this study and it was approved by the hospital ethical
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